Log In or Sign Up

Apixaban: Adverse Effects and Safe Use in Stroke Prevention with DOACs and Liver Function Monitoring

An older patient speaks with her doctor during a checkup, with a glass of water and an unlabeled medication container on the table.

Apixaban is a direct oral anticoagulant (DOAC) that has revolutionized stroke prevention in patients with non-valvular atrial fibrillation. Its mechanism of action is based on the inhibition of factor Xa, which reduces thrombus formation and, consequently, the risk of embolic events. However, as with any anticoagulant treatment, it is crucial to consider the adverse effects and measures for its safe use.

Diving Deeper into the Use of Apixaban

Apixaban has proven effective in reducing the risk of stroke in patients with atrial fibrillation, even in those with subclinical atrial fibrillation detected by implantable devices. A recent study showed that apixaban significantly reduces the risk of stroke or systemic embolism compared to aspirin, although with an increased risk of major bleeding [1].

Regarding safety, apixaban presents a favorable profile compared to other anticoagulants such as warfarin and rivaroxaban. A real-world data analysis indicates that apixaban has a lower risk of major bleeding, including intracranial and gastrointestinal hemorrhages, compared to these agents [2]. Additionally, in patients with advanced chronic kidney disease, apixaban has shown a superior safety profile, with fewer bleeding events compared to warfarin and rivaroxaban [3].

It is important to highlight that, although apixaban does not require routine monitoring of anticoagulation levels, liver function monitoring should be considered in patients with liver dysfunction, as the metabolism of apixaban may be affected in these cases.

Conclusions

Apixaban has established itself as an effective and safe option for stroke prevention in patients with atrial fibrillation. Its safety profile, especially regarding adverse effects related to bleeding, makes it preferable in many cases compared to other anticoagulants. However, it is essential to evaluate each patient individually, considering factors such as renal and liver function, to optimize treatment and minimize risks. Current evidence supports the use of apixaban as a valuable tool in the prevention of thromboembolic events, always under appropriate medical supervision.

Referencias


Created 6/1/2025